Single biomarkers are no longer sufficient to describe complex biological systems such as the tumor microenvironmentor to predict response to targeted therapies. Advances in molecular analysis have led to the understanding that tumor growth is driven by a network of factors and that spatially resolved, multi-omic measurements are the key to understanding this complex network…
bioSyntagma has been awarded “Best Oncology-Focused Precision Medicine Company 2018” by Global Health and Pharma, a UK-based publication that recognizes global companies for improving public health, enhancing patient care, and lowering healthcare costs. This award follows several commercial milestones with strategic partners and Big Pharma using bioSyntagma’s beta-instruments to offer biomarker discovery services.
Striving to eliminate-trial-and-error cancer treatments through predictive analytics and novel diagnostic tools, bioSyntagma has developed a suite of AI-enabled technologies that collectively create the Molecular Fingerprint™. “The Molecular Fingerprint (mPrint) is how personalized medicine transitions from a buzzword to reality,” said David Richardson, CEO of bioSyntagma. “It’s not about a specific drug but about combinations of therapies that precisely match the state of a person’s disease. We are honored GHP recognizes the impact of our work.”
The Arizona State University spin-out company and current client at the Center for Entrepreneurial Innovation is now building more instruments to support broader enrollment in their Early Access Program to provide spatial profiling services. This will enable bioSyntagma to support data acquisition for joint discovery and predictive analytic applications.
A full list of The GHP Technology Awards 2018 winners can be accessed at https://www.ghp-news.com/technology-awards-2018.
bioSyntagma is a precision medicine company dedicated to transforming how cancer is treated by providing deep data on the uniqueness of each person’s cancer. Its suite of platform technologies enables comprehensive, multi-omic and spatial profiling of tissues to get a complete and informed understanding of a patient’s cancer so they can be matched with relevant therapies and provided recommendations to avoid acquiring drug resistance. bioSyntagma serves the needs of clinicians, academic researchers, and drug developers to advance the implementation of precision medicine for cancer treatment.
Phoenix, AZ — bioSyntagma, LLC announced today that the United States Patent and Trademark Office fully issued patent # 15/099,121 for “Method and Apparatus for Extracting and Collecting Single Cells from Formalin-Fixed Paraffin Embedded Tissues,” which bioSyntagma has exclusively licensed from Arizona Technology Enterprises (AzTE). This patent is the foundational technology for the company’s unique microfluidic chip technology, the Light Stream FloCell™. The LightStream FloCell™ allows researchers to examine patient and research tissues to understand how disease-causing cells interact with each other. bioSyntagma’s technology is seen as fundamental to understanding diseases such as cancer, diabetes, and Alzheimer’s by illuminating key cellular interactions in these disease states.
bioSyntagama was founded by three of the named inventors on the patent: David Richardson, Dmitry Derkach, MD, Ph.D., and Colleen Ziegler. bioSyntagma, a Center for Entrepreneurial Innovation client located on the GateWay Community College campus, licensed the patent exclusively from Arizona Technology Enterprises (AzTE). Arizona Technology Enterprises (AzTE) is the exclusive intellectual property management and technology transfer organization for Arizona State University.
“Colleen, Dmitry, and I are the inventors of this device and founded bioSyntagma based on our ability to provide a level of resolution on tissue samples like patient biopsies down to single cells, which provides insight into serious illnesses like cancer. Our technology is positioned to enable doctors and researchers to understand why some people do not respond to cancer treatments, or why some that initially respond become resistant and relapse. We are thrilled that the USPTO recognized the unique contribution this technology can make and awarded a patent for which we are the exclusive license holder from AzTE,” said David Richardson, CEO of bioSyntagma.
The LightStream FloCell™, or tissue chip, allows scientists, researchers, clinicians, and laboratory technologists to identify single cells, or areas of interests from routine biopsy tissues and move those cells using the tissue chip to a standard collection tube for further analysis. This capability can help unlock the underlying mechanisms of diseases such as cancer, where differences in cells can cause resistance to even the latest cancer therapies, as well as, diabetes and other autoimmune diseases like arthritis, and neurological disorders like Alzheimer’s.
bioSyntagma is a precision medicine company dedicated to transforming how cancer is treated by providing deep data on the uniqueness of each person’s cancer. Its suite of platform technologies enables comprehensive, multi-omic and spatial profiling of tissues to get a complete and informed understanding of a patient’s cancer so they can be matched with relevant therapies and provided recommendations to avoid acquiring drug resistance. bioSyntagma serves the needs of clinicians, academic researchers, and drug developers to advance t